"10" . "4"^^ . "[1DF28FFB89C3]" . . . . "What is new in new guidelines for diagnosis and treatment of lipid disorders in adulthood"@en . "Nov\u00E1 Doporu\u010Den\u00ED pro diagnostiku a l\u00E9\u010Dby dyslipidemi\u00ED v dosp\u011Blosti, vypracovan\u00E1 v\u00FDborem \u010Cesk\u00E9 spole\u010Dnosti pro ateroskler\u00F3zu, vych\u00E1zej\u00ED z v\u00FDsledk\u016F nov\u00FDch epidemiologick\u00FDch a interven\u010Dn\u00EDch studi\u00ED s hypolipidemiky a z poznatk\u016F z patofyziologie dyslipidemi\u00ED. Uv\u00E1d\u011Bj\u00ED do praxe nov\u00E9 c\u00EDlov\u00E9 hodnoty LDL-cholesterolu, upozor\u0148uj\u00ED na mo\u017Enost pou\u017Eit\u00ED apolipoproteinu B a non HDL-cholesterolu jako sekund\u00E1rn\u00EDho c\u00EDle u vybran\u00FDch skupin osob (diabetes mellitus, metabolick\u00FD syndrom, hypertriglyceridemie, p\u0159\u00EDtomnost kardiovaskul\u00E1rn\u00EDho onemocn\u011Bn\u00ED s relativn\u011B n\u00EDzkou hladinou LDL-cholesterolu). Zp\u0159es\u0148uj\u00ED odhad individu\u00E1ln\u00EDho rizika kardiovaskul\u00E1rn\u00EDch komplikac\u00ED se zohledn\u011Bn\u00EDm jak klasick\u00FDch, tak i n\u011Bkter\u00FDch nov\u00FDch rizikov\u00FDch faktor\u016F a uv\u00E1d\u011Bj\u00ED mo\u017Enosti detekce preklinick\u00E9 ateroskler\u00F3zy. D\u00E1le jsou uvedeny priority pro l\u00E9\u010Dbu, konkretn\u00ED postupy pro l\u00E9\u010Dbu jednotliv\u00FDch typ\u016F dyslipidemi\u00ED (monoterapie i kombinace hypolipidemik). Zm\u00EDn\u011Bny jsou i postupy nefarmakologick\u00E9 intervence u osob s dyslipidemi\u00ED." . "CZ - \u010Cesk\u00E1 republika" . . "3" . "360271" . . "Intern\u00ED medic\u00EDna pro praxi" . . . "lipid disorders; LDL-cholesterol; apolipoprotein B; cardiovascular disease; hypolipidemics"@en . . . "What is new in new guidelines for diagnosis and treatment of lipid disorders in adulthood"@en . . "New guidelines of diagnosis and treatment of lipid disorders in adulthood, prepared by the committee of the Czech society of atherosclerosis are based on results of new epidemiological and interventional studies with hypolipidemics and on new knowledge on pathophysiology of lipid disorders. They introduce new recommended target levels of LDL-cholesterol, inform about the use of apolipoprotein and non-HDL cholesterol as secondary targets in selected groups of individuals (with diabetes mellitus, metabolic syndrome, hypertriglyceridemy, cardiovascular disease with relatively low level of LDL-cholesterol). They improve the estimation of individual risk of cardiovascular complications taking into account both classical and some of new risk factors and present also the options of detection of preclinical atherosclerosis. Priorities of treatment, algorhytms of treatment of individual disorders (monotherapy and combination of hypolipidemics) are discussed as well as nonpharmacological intervention in patient"@en . . "Vaverkov\u00E1, Helena" . "1212-7299" . "Nov\u00E1 Doporu\u010Den\u00ED pro diagnostiku a l\u00E9\u010Dby dyslipidemi\u00ED v dosp\u011Blosti, vypracovan\u00E1 v\u00FDborem \u010Cesk\u00E9 spole\u010Dnosti pro ateroskler\u00F3zu, vych\u00E1zej\u00ED z v\u00FDsledk\u016F nov\u00FDch epidemiologick\u00FDch a interven\u010Dn\u00EDch studi\u00ED s hypolipidemiky a z poznatk\u016F z patofyziologie dyslipidemi\u00ED. Uv\u00E1d\u011Bj\u00ED do praxe nov\u00E9 c\u00EDlov\u00E9 hodnoty LDL-cholesterolu, upozor\u0148uj\u00ED na mo\u017Enost pou\u017Eit\u00ED apolipoproteinu B a non HDL-cholesterolu jako sekund\u00E1rn\u00EDho c\u00EDle u vybran\u00FDch skupin osob (diabetes mellitus, metabolick\u00FD syndrom, hypertriglyceridemie, p\u0159\u00EDtomnost kardiovaskul\u00E1rn\u00EDho onemocn\u011Bn\u00ED s relativn\u011B n\u00EDzkou hladinou LDL-cholesterolu). Zp\u0159es\u0148uj\u00ED odhad individu\u00E1ln\u00EDho rizika kardiovaskul\u00E1rn\u00EDch komplikac\u00ED se zohledn\u011Bn\u00EDm jak klasick\u00FDch, tak i n\u011Bkter\u00FDch nov\u00FDch rizikov\u00FDch faktor\u016F a uv\u00E1d\u011Bj\u00ED mo\u017Enosti detekce preklinick\u00E9 ateroskler\u00F3zy. D\u00E1le jsou uvedeny priority pro l\u00E9\u010Dbu, konkretn\u00ED postupy pro l\u00E9\u010Dbu jednotliv\u00FDch typ\u016F dyslipidemi\u00ED (monoterapie i kombinace hypolipidemik). Zm\u00EDn\u011Bny jsou i postupy nefarmakologick\u00E9 intervence u osob s dyslipidemi\u00ED."@cs . . "1"^^ . . "So\u0161ka, Vladim\u00EDr" . "Co p\u0159in\u00E1\u0161ej\u00ED nov\u00E1 Doporu\u010Den\u00ED pro diagnostiku a l\u00E9\u010Dbu dyslipidemi\u00ED" . "Co p\u0159in\u00E1\u0161ej\u00ED nov\u00E1 Doporu\u010Den\u00ED pro diagnostiku a l\u00E9\u010Dbu dyslipidemi\u00ED"@cs . . "RIV/61989592:15110/08:00007156!RIV09-MSM-15110___" . "2"^^ . "Co p\u0159in\u00E1\u0161ej\u00ED nov\u00E1 Doporu\u010Den\u00ED pro diagnostiku a l\u00E9\u010Dbu dyslipidemi\u00ED" . . "Co p\u0159in\u00E1\u0161ej\u00ED nov\u00E1 Doporu\u010Den\u00ED pro diagnostiku a l\u00E9\u010Dbu dyslipidemi\u00ED"@cs . . "RIV/61989592:15110/08:00007156" . "S" . "15110" .